Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data

[1] Sarwar N(2010)Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 375 2215-2222

[2] Gao P(1999)Hyperglycemia and cardiovascular disease in type 2 diabetes Diabetes 48 937-942

[3] Seshasai SR(2016)Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus—mechanisms, management, and clinical considerations Circulation 133 2459-2502

[4] Gobin R(2015)SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials Diabetes Vasc Dis Res 12 90-100

[5] Kaptoge S(2007)Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis Scand J Clin Lab Investig 67 786-800

[6] Di Angelantonio E(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 140-149

[7] Ingelsson E(2013)Influence of chronic comorbidity and medication on the efficacy of treatment in patients with diabetes in general practice Br J Gen Pract 63 e267-e273

[8] Lawlor DA(2011)Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects Diabetes Obes Metab 13 669-672

[9] Selvin E(2013)Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus J Clin Endocrinol Metab 98 E867-E871

[10] Stampfer M(2015)Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus Ann N Y Acad Sci 1358 28-43

[1] Sarwar N(2010)Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 375 2215-2222

[2] Gao P(1999)Hyperglycemia and cardiovascular disease in type 2 diabetes Diabetes 48 937-942

[3] Seshasai SR(2016)Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus—mechanisms, management, and clinical considerations Circulation 133 2459-2502

[4] Gobin R(2015)SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials Diabetes Vasc Dis Res 12 90-100

[5] Kaptoge S(2007)Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis Scand J Clin Lab Investig 67 786-800

[6] Di Angelantonio E(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 140-149

[7] Ingelsson E(2013)Influence of chronic comorbidity and medication on the efficacy of treatment in patients with diabetes in general practice Br J Gen Pract 63 e267-e273

[8] Lawlor DA(2011)Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects Diabetes Obes Metab 13 669-672

[9] Selvin E(2013)Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus J Clin Endocrinol Metab 98 E867-E871

[10] Stampfer M(2015)Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus Ann N Y Acad Sci 1358 28-43